For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.mycme.com/courses/clinical-updates-in-schizophrenia-10097 Summary In this PsychTalk podcast/webcast episode, Drs. Gregory Mattingly and Lisa Harding go through the evolving landscape of schizophrenia treatments. Listen as they discuss the pros and cons of various second-generation antipsychotics, the science behind muscarinic modulation for psychosis, and recent updates in clozapine prescribing. At the end of the session, the doctors answer several audience questions to enhance your understanding of these developments and how they apply to clinical practice. This podcast was recorded and is being used with permission of the presenters. Learning Objectives At the conclusion of this activity, participants should be better able to: Integrate recent clinical data on antipsychotic treatments and relapse prevention strategies into management plans for patients with schizophrenia Describe the role of muscarinic modulation in psychosis This activity is accredited for CME/CE Credit This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians. The National Association for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.75 contact hours (which includes 0.75 hours of pharmacology). For additional information about the accreditation of this program, please contact NACE at
[email protected] . Summary of Individual Disclosures Please review faculty and planner disclosures here . Disclosure of Commercial Support This educational activity is not commercially supported. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
